Nilsine Partners’s Invesco Pharmaceuticals ETF PJP Stock Holding History

Nilsine Partners’s Portfolio PJP Stock Details PJP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.59M	Buy	+12,855	New	+$1.6M	0.11%	174

Other funds holding PJP

LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return

Trek Financial Scottsdale, Arizona $2.16B AUM 42.56% 1-Year Est. Return

Vicus Capital State College, Pennsylvania $1.58B AUM 16.34% 1-Year Est. Return

Joseph Group Capital Management Columbus, Ohio $562M AUM 15.17% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Trilogy Capital Irvine, California $2.61B AUM 14.55% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

Institute for Wealth Management Denver, Colorado $1.13B AUM 31.46% 1-Year Est. Return

Outlook Wealth Advisors Shenandoah, Texas $470M AUM 20.06% 1-Year Est. Return

Dumont & Blake Investment Advisors Princeton, New Jersey $398M AUM 22.72% 1-Year Est. Return

Nilsine Partners's PJP Position: Q3 2026 in Review

Nilsine Partners opened a new position in Invesco Pharmaceuticals ETF (PJP) in Q3 2026: 12,855 shares worth $1.59M. The stake represents 0.11% of the portfolio and ranks #174 among its holdings.

61 funds tracked by Wall St. Rank hold PJP as of Q3 2026.

Nilsine Partners held 12,855 shares of Invesco Pharmaceuticals ETF worth $1.59M as of Q3 2026.
Invesco Pharmaceuticals ETF was a new Nilsine Partners position in Q3 2026.
Invesco Pharmaceuticals ETF made up 0.11% of Nilsine Partners's portfolio in Q3 2026, its #174 holding.
61 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q3 2026.

Based on Nilsine Partners's 13F filing for Q3 2026, filed 2 Nov 2026.